igarette smoking is one of the major classical risk factors for atherosclerosis and cardiovascular disease. [1] [2] [3] [4] However, both the precise mechanism(s) by which smoking promotes atherosclerosis and is its relationship with other risk factors are unknown. There is now increasing evidence from basic, pathological and clinical research that atherosclerosis is an inflammatory disease [5] [6] [7] initiated by endothelial injury and subsequent dysfunction via deleterious effects of risk factors such as oxidized low-density lipoprotein (LDL), hypertension and hyperglycemia. [5] [6] [7] [8] [9] We and others have shown that both the coronary and peripheral artery endothelium is injured and dysfunctional in smokers, [10] [11] [12] [13] [14] [15] [16] [17] [18] and that the administration of antioxidants improves endothelial dysfunction in both smokers and in vitro experiments, indicating that reactive oxygen species (ROS) are involved in the genesis of the endothelial dysfunction in smokers. [14] [15] [19] [20] [21] [22] However, what is not well known is whether smoking is associated with inflammation and what is its relationship with other risk factors.
The present study was designed to examine whether smoking is associated with inflammation, as well as other classical risk factors, by comparing clinical and laboratory data between smokers and those who have never smoked.
defined to have smoked more than 10 /day for more than 10 years. All patients gave their written informed consent to participate in this study, and the protocol was approved by the institutional review board.
Laboratory Methods
Fasting blood samples were drawn by venipuncture for hematological analysis and measurement of serum levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C) and apolipoprotein done by Beckman/Coulter autoanalyzer using standard laboratory procedures. High-sensitivity CRP was measured by automated immunoassays using the Synchron LX20 Pro system (Beckman/Coulter), 23 which is sensitive enough to detect 0.020 mg/dl. Remnant-like particle cholesterol (RLP-C) levels were isolated from the serum to an immuno-affinity mixed gel containing anti-apoA1 and anti-apoB100 monoclonal antibodies (Japan Immunoresearch Laboratories). 24 Fibrinogen levels were measured by turbidimetric immunoassay method. 25 
Statistical Analysis
Differences in the variables among the 3 groups were evaluated with analysis of variance followed by the Bonferroni t-test. Differences with a p-value <0.05 were considered statistically significant. Data are presented as mean ± SD.
Results
As shown in Table 1 , the percentage of subjects with coronary spastic angina was significantly higher in the current-smoker group than in either the past-smoker group or never-smoked group. results. The current-smoker group was significantly younger than the never-smoked group. There was no significant difference in the body mass index among the 3 groups. Diastolic blood pressure was higher in the current-smoker group than in the never-smoked group. Blood leukocyte counts, including those of lymphocytes, were significantly higher in the current-smoker group than the never-smoked group, although these values were within normal limits in all 3 groups. Plasma levels of CRP and fibrinogen were also significantly elevated in the current-smoker group compared with the never-smoked group, although these values were almost within normal limits. All these values were intermediate in the past-smoker group. These results indicate that smoking is associated with low-grade inflammation, or a propensity to inflammation. In addition to higher levels of blood CRP and fibrinogen, the platelet count was also significantly higher in the current-smoker group than in the never-smoked group, which strongly suggests that smokers also have propensity to platelet aggregability and blood coagulability, indicating a prothrombotic state.
The plasma level of HDL-C was significantly lower and those of TG, RLP-C, and apolipoprotein-B were significantly higher in the current-smoker group than in the never-smoked group, whereas there was no significant difference in the levels of TC and LDL-C among the 3 groups and these values were almost within normal limits. These values also were intermediate in the past-smoker group. Taken together, the results indicate that smokers have an atherogenic blood lipid profile and are more prone to develop atherosclerosis than subjects who have never smoked. There was no significant difference among the 3 groups in the number of significantly diseased major coronary arteries as defined >75% narrowing of the diameter after nitroglycerin administration assessed by coronary angiography. 
Discussion
Cigarette smoking is a major risk factors for coronary atherosclerosis [1] [2] [3] [4] and there is now increasing evidence that atherosclerosis is an inflammatory disease. [5] [6] [7] It is thus possible that smoking induces inflammation, thereby promoting atherosclerosis, which is initiated by endothelial injury and dysfunction. [5] [6] [7] [8] [9] We and others have shown that the endothelium of both the coronary and peripheral arteries is injured and dysfunctional, as indicated by diminished bioavailability of nitric oxide (NO), in smokers. [10] [11] [12] [13] [14] [15] [16] The present study shows that inflammation markers, such as the blood levels of CRP, fibrinogen, leukocytes, particularly lymphocytes, which are a manifestation of chronic inflammation, 26 are elevated in current smokers compared with the never-smoked, although they are almost within normal limits. The levels of these markers were intermediate in the past-smoker group. The results of this study agree with those of 2 similar studies done in apparently healthy populations recently reported from the United States. 27, 28 The evidence from the present study thus strongly suggests that chronic low-grade inflammation and/or a propensity to inflammation exist in current smokers and to a lesser degree in past smokers. Because both CRP and fibrinogen are produced in the liver by stimulation of inflammatory cytokines mainly through interleukin (IL)-6, 26, 29, 30 the elevated plasma levels of these inflammatory markers may indicate increased levels of IL-6 together with other pro-inflammatory cytokines in smokers. CRP is also produced within human coronary arteries and is expressed preferentially in diseased vessels and may also itself play a role in repressing the production of NO and diminished NO bioavailability, resulting in endothelial dysfunction. [30] [31] [32] It is now clearly established that CRP predicts future risk for cardiovascular diseases in apparently healthy persons, independent of the classical risk factors. 4, [29] [30] [31] We and others have also shown that smoking generates ROS, which suppress endothelial NO activity. [13] [14] [15] [16] [19] [20] [21] [22] ROS, in addition to modifying LDL into oxidized LDL, and thus initiating atherosclerosis, also activates DNA binding factors such as activator protein-1 and nuclear factor-B which, in turn, lead to transcription of several pro-inflammatory genes, including those for adhesion molecules and inflammatory cytokines. [32] [33] [34] Thus, ROS play a crucial role in the pathogenesis of atherosclerosis. 33, 34 In the current smokers the plasma level of HDL-C was lower and the levels of TG, RLP-C, and apolipoprotein-B, were higher than in the never-smoked, but there was no difference in the level of LDL-C between smokers and the never-smoked group. These lipoprotein profiles are similar to those seen in the "metabolic syndrome", suggesting that smoking may play a similar role in promoting atherosclerosis, as recent reports indicate that blood levels of inflammatory markers are elevated in patients with metabolic syndrome. [35] [36] [37] Because IL-6 promotes the synthesis of fatty acid and suppresses lipoprotein lipase, the increased levels of TG, RLP-C and apolipoprotein-B in smokers may be caused mainly by elevation of IL-6 or other inflammatory cytokines. 26, 29, 38 It is interesting to note that there was no significant difference in the levels of LDL-C among smokers and the never-smoked, despite the fact that LDL-C is well established as a critical factor in the pathogenesis of atherosclerosis. [4] [5] [6] [7] [8] [9] We and others have shown that RLP-C is an important risk factor for atherosclerosis, [39] [40] [41] [42] [43] but there has not been a report linking smoking with RLP-C and thus this is first to show elevated levels in smokers as compared with non-smokers.
The plasma levels of platelets were also increased in the smokers, although these values were within normal limits in all 3 groups. The increased platelet count, together with elevated levels of CRP and fibrinogen, indicate an increased propensity to thrombosis in smokers. 9,32 IL-6 is also known to stimulate the production of platelets, as well as leukocytes; 26, 29, 44 however, so far as we know, there has not been a report of an association between smoking and platelet count and this study is probably the first to demonstrate that smokers have an increased platelet count.
It is thus quite probable that smoking induces inflammation, an atherogenic lipid profile and a propensity to thrombosis, thereby promoting the development of coronary atherothrombosis. The level of inflammation, prothrombotic state and atherogenic lipids were reduced or tended to be reduced in past smokers compared with the current smokers, which suggests that ceasing smoking may alleviate acceleration of atherosclerosis. Indeed, cessation of smoking constitutes the single most important intervention in preventive cardiology. 45 The present study differs from previous similar ones by the fact that all study subjects underwent coronary angiography on suspicion of CAD. There was no significant difference between smokers and non-smokers in the number of diseased coronary arteries. The results thus show that the levels of markers of inflammation, prothrombotic state, and/or atherogenic lipid profile do not correlate well with the degree or extent of coronary narrowing as assessed by angiography, which is in agreement with previous studies. 32, 46, 47 Our study therefore strongly suggests that these markers are not a good indicator of the "atherosclerotic burden" as assessed by angiography, but are probably linked to the process of inflammation or prothrombotic state or instability of atherosclerotic lesions. 47 It should also be noted that the smokers had the higher levels of these markers despite the fact that they were significantly younger than the non-smokers and that the levels of these markers increase with age. [48] [49] [50] The results thus also suggests that smoking accelerates aging. [48] [49] [50] The present study also showed that the percentage of patients with coronary spastic angina was significantly higher in the current-smoker group than in either the past-smoker group or never-smoked group. This result is interesting in view of the fact that smoking is the most important correctable risk factor for coronary spasm 2 and it suggests strongly that cessation of smoking is critical for prevention of coronary spasm.
The limitations of the present study include its cross-sectional nature, limited applicability to the general population because of the selection criteria, the number of study subjects, and the limitation of angiography in assessing coronary atherosclerosis.
In conclusion, smokers had elevated blood levels of inflammatory markers such as blood leukocyte count, CRP, and fibrinogen, thrombogenic markers including CRP, fibrinogen and platelet count, and had an atherogenic lipid profile, including decreased levels of HDL-C and increased levels of TG, RLP-C and apolipoprotein-B, among a group of patients without apparent inflammation who underwent coronary angiography on suspicion of CAD.
